Pfizer and BioNTech have made history with their COVID-19 vaccine, as it is the first to enter the U.S. market after Phase 3 clinical trial results showing 95% efficacy. The mRNA vaccine is being allocated for emergency use to hospitals nationwide, and by the end of 2021 hundreds of millions of Americans will be vaccinated. The Center for Disease Control’s Advisory Committee on Immunization Practices will manage distribution of the breakthrough vaccine in partnership with Operation Warp Speed. Pfizer and BioNTech continue to collaborate and plan with global public health entities to plan for global distribution.
Learn more here.